

SKINVISIBLE INC
Form 10QSB
May 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-QSB

QUARTLERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

ended March 31, 2004

For the quarterly period

TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 000-25911

SKINVISIBLE, INC.
(Exact name of Small Business Issuer as specified in its charter)

NEVADA
(State or other jurisdiction of incorporation)

88-0344219

(IRS Employer Identification No.)

6320 SOUTH SANDHILL ROAD, SUITE 10, LAS VEGAS, NEVADA 89120
(Address of principal executive offices)

702-433-7154
(Issuer's telephone number)

(Former name, former address and former fiscal year if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

48,714,808 shares of common stock as of March 31, 2004

Transitional Small Business Disclosure Format (check one): Yes No

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Our general unaudited financial statements included with the Form 10QSB are as follows:

- (a) Balance Sheets as of March 31, 2004 (unaudited), and March 31, 2003;
- (b) Statements of Operations three months ended March 31, 2004, and March 31, 2003;
- (c) Statement of Stockholders Equity January 1, 2004 to March 31, 2004 (unaudited);
- (d) Statement of Cash Flow three months ended March 31, 2004 and 2003 (unaudited);
- (e) Notes to Unaudited Financial Statements.

The unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-QSB. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for this interim period are not necessarily indicative of the results that can be expected for the full year.

**SKINVISIBLE, INC.
CONSOLIDATED FINANCIAL STATEMENTS**

TABLE OF CONTENTS

PAGE NO.

Consolidated Financial statements	
Consolidated balance sheets	2
Consolidated statements of operations	3
Consolidated statements of stockholders equity	4
Consolidated statements of cash flows	5

F1

SKINVISIBLE, INC.
CONSOLIDATED BALANCE SHEET

	31, 2004	March 31, 2003		March
ASSETS				
Current assets				
Cash	\$	388,213	\$	--
Accounts receivable		11,341		54,495
Inventory		80,322		118,776
Due from related party		15,103		--
Prepaid expense and other current assets		785		57,138
		495,764		230,409
Total current assets		495,764		230,409
Fixed assets, net		67,265		175,080
Intangible and other assets				
Patents and trademarks, net		25,319		30,071
License and distributor rights		50,000		200,000
Prepaid royalty fees		1,200,000		1,000,000
		1,838,348	\$	1,635,560
Total assets	\$	1,838,348	\$	1,635,560
LIABILITIES AND				
STOCKHOLDERS' EQUITY				
Current liabilities				
Bank overdraft	\$	--	\$	2,596
Accounts payable and accrued liabilities		466,881		485,893
Unearned revenue		250,000		-
Loans payable		247		148,722
		717,128		637,211
Total current liabilities		717,128		637,211
Long-term liabilities				
Stock subscriptions payable		549,894		--
		549,894		--

Edgar Filing: SKINVISIBLE INC - Form 10QSB

Total liabilities	1,267,022	637,211
Commitments and contingencies	--	--
Stockholders' equity		
Common stock; \$0.001 par value; 100,000,000 shares authorized, 48,715,000 and 38,882,000 shares issued and outstanding	48,715	38,882
Additional paid-in capital	10,450,665	9,466,908
Accumulated deficit	(9,928,054)	(8,507,441)
Total stockholders' equity	<u>571,326</u>	<u>998,349</u>
Total liabilities and stockholders' equity	<u>\$ 1,838,348</u>	<u>\$ 1,635,560</u>

See Accompanying Notes and Accountants' Report

F2

SKINVISIBLE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

three ended 2004	For the three months ended March 31, 2003		For the months March 31,
Revenues	\$ 59,513	\$	65,509
Cost of revenues	<u>22,455</u>		<u>19,795</u>
Gross profit	37,058		45,714
Operating expenses			
Depreciation and amortization	14,047		16,395
Selling general and administrative	194,866		90,781
Total operating expenses	<u>208,913</u>		<u>107,176</u>
Loss before provision for income taxes	(171,855)		(61,462)
Provision for income taxes	--		--

Edgar Filing: SKINVISIBLE INC - Form 10QSB

Net loss	\$	(171,855)	\$	(61,462)
Basic income (loss) per common share	\$	(0.00)	\$	(0.00)
Diluted income (loss) per common share	\$	(0.00)	\$	(0.00)
Basic weighted average common shares outstanding		48,715,000		38,820,539

See Accompanying Notes and Accountants' Report

F3

SKINVISIBLE, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Stock Capital	Additional Deficit	Accumulated Equity	Stockholders'	Common		
				Shares	Amount	Paid-in
Balance, January 1, 2003		38,789,808	38,790	9,442,838	(8,445,979)	1,035,649
Issuance pursuant to stock offering & option plan		92,192	92	24,070	-	24,162
Net loss		--	--	--	(61,462)	(61,462)
Balance, March 31, 2003		<u>38,882,000</u>	<u>\$ 38,882</u>	<u>\$ 9,466,908</u>	<u>\$ (8,507,441)</u>	<u>\$ 998,349</u>
Balance, January 1, 2004		48,714,618	48,715	10,450,665	(9,756,199)	743,181
Net loss		--	--	--	(171,855)	(171,855)
Balance, March 31, 2004		<u>48,714,618</u>	<u>\$ 48,715</u>	<u>\$ 10,450,665</u>	<u>\$ (9,928,054)</u>	<u>\$ 571,326</u>

See Accompanying Notes and Accountants' Report

F4

SKINVISIBLE, INC
CONSOLIDATES STATEMENTS OF CASH FLOWS

the three ended March 31, 2003	For the three months ended	For months March 31, 2004
Cash flows from operating activities:		
Net loss	\$ (171,855)	\$ (61,462)
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation and amortization	14,047	16,395
Changes in operating assets and liabilities:		
Change in inventory	(3,634)	4,930
Change in accounts receivable	16,836	(9,722)
Change in prepaid expenses and other current assets	(15,888)	(3,825)
Change in bank overdraft	(762)	2,596
Change in accounts payable and accrued liabilities	(207,809)	22,706
Change in loan payable	(42,616)	--
Change in stock subscription payable	549,894	--
Change in unearned revenue	250,000	--
	<hr/>	<hr/>
Net cash used by operating activities	388,213	(28,382)
Cash flows from investing activities:		
Purchase of fixed assets	--	--
	<hr/>	<hr/>
Net cash used by investing activities	--	--
Cash flows from financing activities:		
Proceeds from issuance of common stock	--	24,162
Principal payments on notes payable	--	(402)
	<hr/>	<hr/>
Net cash provided (used) by financing activities	--	23,760
	<hr/>	<hr/>
Net change in cash	388,213	(4,622)
Cash, beginning of period	--	4,622
	<hr/>	<hr/>
Cash, end of period	\$ 388,213	\$ --
	<hr/>	<hr/>

Supplemental disclosure of cash flow information:

Cash paid for interest	\$	4,051	\$	2,526
------------------------	----	-------	----	-------

See Accompanying Notes and Accountants' Report

F5

SKINVISIBLE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General

Skinvisible, Inc. (formerly Microbial Solutions, Inc.) was incorporated on March 6, 1998 in the state of Nevada. Skinvisible, Inc. immediately acquired 100% ownership of Skinvisible Pharmaceutical, Inc. (formerly Manloe Labs, Inc.) also a Nevada corporation.

Skinvisible, Inc. and its subsidiaries, (collectively referred to as the "Company" or "SKVI") is focused on the development and manufacture of innovative topical polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Skinvisible's antibacterial/antimicrobial hand sanitizer formulations, available for private label commercialization opportunities, offer skincare solutions for the healthcare, food service, industrial, cosmetic and salon industries, as well as for personal use in the retail marketplace. The Company maintains manufacturing, executive and sales offices at Las Vegas, Nevada.

Name Change

On February 26, 1999, the company completed the legal process of changing its name from Microbial Solutions, Inc. to Skinvisible, Inc. The subsidiary's name of Manloe Labs, Inc. was also changed on February 26, 1999 to Skinvisible Pharmaceuticals, Inc.

During 1999, the company also formed a subsidiary titled Skinvisible International, Inc. and Skinvisible Pharmaceuticals (Canada), Inc. On January 1, 2000, the Company decided to discontinue operations of its subsidiary, Skinvisible International, Inc.

On April 20, 2000, the Company formed a subsidiary titled Safe4Hours, Inc. for the purpose of marketing its own proprietary brands of products.

Basis of Presentation

The consolidated financial statements include the accounts of Skinvisible, Inc. and its subsidiaries, Skinvisible Pharmaceuticals, Inc., Skinvisible Pharmaceuticals (Canada), Inc., and Safe4Hours, Inc. All material intercompany balances have been eliminated.

The Company reports revenue and expenses using the accrual method of accounting for financial and tax reporting purposes. All reported amounts are in US dollars.

Use of Estimates

Management uses estimates and assumptions in preparing these financial statements in accordance with generally accepted accounting principles. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses.

F6

SKINVISIBLE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Pro Forma Compensation Expense

The Company accounts for costs of stock-based compensation in accordance with APB No. 25, "Accounting for Stock Based Compensation" instead of the fair value based method in SFAS No. 123. No pro forma compensation expense is reported in these financial statements for the period ended March 31, 2004.

Inventories

Inventories are accounted for at cost utilizing the first-in first-out basis. Inventory at any given time consists of raw materials, products and packaging held for resale.

Property and Equipment

Property and equipment are stated at historical cost.

Depreciation, Amortization and Capitalization

The Company records depreciation and amortization using both straight-line and declining balance methods over the estimated useful life of the assets (five to seven years).

Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals and replacements that increase the property's useful life are capitalized. Property sold or retired, together with the related accumulated depreciation, is removed from the appropriate accounts and the resultant gain or loss is included in net income.

Income Taxes

The company accounts for its income taxes in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes". Under Statement 109, a liability method is used whereby deferred tax assets and liabilities are determined based on temporary differences between basis used for financial reporting

and income tax reporting purposes. Income taxes are provided based on tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not, that the Company will not realize the tax assets through future operations.

Fair Value of Financial Instruments

Financial accounting Standards Statement No. 107, "Disclosures About Fair Value of Financial Instruments", requires the Company to disclose, when reasonably attainable, the fair market values of its assets and liabilities, which are deemed to be financial instruments. The Company's financial instruments consist primarily of cash and certain investments.

F7

SKINVISIBLE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Per Share Information

The Company computes per share information by dividing the net loss for the period presented by the weighted average number of shares outstanding during such period. The effect of common stock equivalents would be antidilutive and is not included in net loss per share calculations.

NOTE 2 - PROVISION FOR INCOME TAXES

The provision for income taxes for the periods ended March 31, 2004 and 2003 represents the minimum state income tax expense of the Company, which is not considered significant.

NOTE 3 - LOAN PAYABLE

During the periods ended March 31, 2004 and 2003, and December 31, 2003 the Company had unsecured loans payable with an interest rate of 10% per annum. As of March 31, 2004, outstanding loans payable with interest were in the amount of \$247.

NOTE 4 - COMMITMENTS AND CONTINGENCIES

Operating Leases

The company presently leases 8,556 square feet of manufacturing and office space on a month-to-month basis. The company's operating lease terminated on May 31, 2002 and negotiations are currently underway for a renewal of the lease for these premises.

Licensing, Royalty and Consulting Agreements

The Company has currently entered into, and will continue to enter into, product licensing, royalty and consulting agreements that the Company's board of directors determines will enhance the Company's ability to market innovative products in a competitive field.

At March 31, 2004, the company has future royalty payment commitments totaling approximately \$372,000.

NOTE 5 - STOCK OPTIONS

At March 31, 2004, the Company had outstanding stock options with exercise prices of \$0.10 per share, as incentives for employee and consultant performance. No stock options were granted during the three months ended March 31, 2004. The exercise of any or all of these options would cause reported losses per share to decrease.

F8

SKINVISIBLE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 GOING CONCERN

Future issuances of the Company's equity or debt securities will be required in order for the Company to continue to finance its operations. The Company's present revenues are insufficient to meet operating expenses.

The consolidated financial statements of the Company have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of \$9,928,054 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

F9

Item 2. Management's Discussion and Analysis or Plan of Operation.

Historical results and trends should not be taken as indicative of future operations. Management's statements contained in this report that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual

results may differ materially from those included in the forward-looking statements. The Company intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and is including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words "believe," "expect," "intend," "anticipate," "estimate," "project," "prospects," or similar expressions. The Company's ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on the operations and future prospects of the Company on a consolidated basis include, but are not limited to: changes in economic conditions generally and the retail pharmaceutical market specifically, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Further information concerning the Company and its business, including additional factors that could materially affect the Company's financial results, is included herein and in the Company's other filings with the Securities and Exchange Commission.

Overview

We were organized as a Nevada corporation on March 5, 1998 under the name "Microbial Solutions, Inc." On February 26, 1999, we changed our name to "Skinvisible, Inc."

We are focused on the development of innovative topical polymer-based delivery systems and technologies, incorporating our proprietary process for combining hydrophilic and hydrophobic polymers into stable water emulsions. When topically applied, products incorporating our delivery systems adhere to the skin's outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. Proven or potential applications identified to date include antimicrobial hand sanitizers, suncare and lipcare formulations, skincare moisturizers, anti-fungals, insect repellents, acne, eczema, and psoriasis treatment applications.

Our primary business objective is to license our technologies and/or sell our delivery systems to established brand manufacturers and marketers of topical prescription Rx, over-the-counter, cosmetic and skincare products to provide enhanced performance capabilities. Our short-term strategy includes revenue generation from private label business opportunities for our antimicrobial hand sanitizer formulations. We are also offering private label opportunities for our clinically tested sunscreen formulation which allows labeling as "Very Water Resistant with an SPF of 30" in accordance with FDA Final Sunscreen Monograph requirements. In addition, we also manufacture other skincare products such as moisture creams and sunless tanning products which are sold as both lotions and spray-ons for air brush tanning.

Plan of Operation

We are focused on the development of innovative topical polymer-based delivery systems and technologies, incorporating our proprietary process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Our plan for the next twelve months is to continue to license our technologies and/or sell our delivery systems to established brand manufacturers and marketers of topical prescription Rx, over-the-counter, cosmetic and skincare products to provide enhanced performance capabilities. We are also seeking to generate revenue by offering private label business opportunities for products that utilize our topical polymer-based delivery systems and technologies such as our antimicrobial hand sanitizer formulations.

In furtherance of our business plan, on March 30, 2004 we signed a letter of intent with Dermal Defense, Inc. ("Dermal Defense"), a Michigan corporation, to grant Dermal Defense the exclusive marketing and distribution rights to the antimicrobial hand sanitizer product we manufacture that is identified as Triclosan 1% formula (the "Product") in the North American countries of Canada, United States, and Mexico in exchange for \$1,000,000 USD plus a 5.0% royalty fee on gross revenues received from sales of the product. Under the terms of this letter of intent, we received a non-refundable deposit in the amount of \$250,000 and the remaining \$750,000 of the purchase price is payable quarterly in an amount determined to be the greater of \$75,000 or 5% of product sales for the quarterly period provided that the parties are successful in negotiating a formalized licensing agreement. Under the terms agreed upon in the letter of intent, the rights to market and distribute the antimicrobial hand sanitizer product in the North American countries of Canada, United States, and Mexico were transferred and assigned to Dermal Defense upon the signing of the letter of intent and payment of the \$250,000 non-refundable deposit. The parties are in the process of negotiating a formalized licensing agreement.

Over the next twelve months we will seek to expand the distribution of our innovative topical polymer-based delivery systems in the European market with established companies in the pharmaceutical and cosmetic industry.

We have recently developed sunless tanning products which are sold as both lotions and spray-ons for air brush tanning that incorporate our topical polymer-based delivery systems. Over the next twelve months we will be seeking to generate revenue by offering private label business opportunities and/or enter into agreements granting distributors the exclusive marketing and distribution rights for these sunless tanning products.

Over the last year we have been seeking to develop new topical products. Our plan is to continue these efforts and complete the development of a DEET free mosquito repellent that incorporates our topical polymer-based delivery systems. Over the next twelve months we expect to launch this product line.

Over the last several years we have taken steps to protect our intellectual property. We will continue to protect intellectual property rights and plan to seek patent protection for our Invisicare topical compositions and our methodology for manufacturing and utilization of numerous delivery systems and related applications in Canada, Europe, China, India, Japan, and Australia.

Assets

As of March 31, 2004, we had total assets in the amount of \$1,838,348, compared to total assets in the amount of \$1,461,496 as of December 31, 2003. The increase in our total assets is primarily attributable to cash we received from a private placement of our common stock. During the

4

reporting period, we raised \$547,894 and issued 5,478,940 shares of restricted common stock plus 2,739,470 warrants to 3 accredited investors. As of March 31, 2004 we had cash in the amount of \$388,213, compared to \$0 cash as of December 31, 2003.

Our largest asset is prepaid royalty fees in the amount of \$1,200,000.

Liabilities and Stockholders Equity

Our total liabilities as of March 31, 2004 were \$1,267,022, compared to total assets in the amount of \$718,315 as of December 31, 2003. The increase in our total liabilities is primarily attributable to us recording a long term liability for stock subscriptions payable in the amount of \$549,894 during the reporting period.

Our operations for the reporting period were primarily funded through equity financings. Stockholders' equity was \$571,326 as of March 31, 2004.

Results of Operations

Our revenue for the three month period ended March 31, 2004 was \$59,513, compared to \$65,509 for the three month period ended March 31, 2003. Gross profit for the three month period ended March 31, 2004 decreased to \$37,058 from \$45,714 for the three month period ended March 31, 2003. The decrease in gross profit in the three month period ended March 31, 2004 when compared to the same three month period in the prior year is attributable to an increase in our cost of revenues and reduced sales.

Our operating expenses increased to \$208,913 for the three month period ended March 31, 2004 from \$107,176 for the three month period ended March 31, 2003. The increase in expenses was due primarily to a significant increase in our selling and administrative expenses. Our selling and administrative expenses for the three month period ended March 31, 2004 were \$194,866, compared to \$90,781 for the same three month period in the prior year. An increase in salaries accounted for a significant portion of the increase in selling and administrative expenses.

The Company had net losses of \$171,855 for the three month period ended March 31, 2004, an increase from \$61,462 for the same three period in the prior year. Our loss was primarily attributable to operating expenses. The losses were funded primarily by equity financings.

Liquidity and Capital Resources

As of March 31, 2004, we maintained \$388,213 in cash. Management believes that we will have sufficient capital to finance our operations for the next twelve months based upon an equity financing received in the reporting period coupled with revenues anticipated to be received in the current fiscal year.

On March 31, 2004, we had a working capital deficit of \$221,364.

Off Balance Sheet Arrangements

As of March 31, 2004, there were no off balance sheet arrangements.

Going Concern

Our independent auditors have stated in their Auditor's Report included in the Form 10-KSB that the Company has incurred operating losses, accumulated deficit, and negative cash flow from operations. As of December 31, 2003, we had incurred cumulative net losses of approximately \$9,638,000.

These factors, among others, raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should we be unable to continue as a going concern.

Revenue Recognition

Revenues are recognized during the period in which the revenues are received. Costs and expenses are recognized during the period in which they are incurred.

Item 3. Controls and Procedures.

The Company carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2004. This evaluation was carried out under the supervision and with the participation of the Company's management, including Mr. Terry Howlett, the Company's Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective. There have been no significant changes in the Company's internal controls or in other factors, which could significantly affect internal controls subsequent to the date the Company carried out its evaluation.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in Company reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed under the Exchange Act is accumulated and communicated to management, including the Company's Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

6

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are not aware of any pending litigation against the Company, its officers, directors, controlling shareholders or affiliates that we believe are of a material nature or that could negatively affect the net worth of the Company.

Item 2. Changes in Securities

During the reporting period, we raised \$547,894 in the form of a private placement and issued 5,478,940 shares of restricted common stock plus 2,739,470 warrants to 3 accredited investors. The warrant gave the holders the right to purchase one share of common stock at \$0.15 per share on or before March 26, 2005, then at \$0.20 per share on or before the close of business on March 25, 2006. These shares were issued pursuant to the exemption available under Section 4(2) of the Securities Act of 1933. Each purchaser represented his or her intention to acquire the securities for investment intent only and not with a view toward distribution. Each investor was given adequate information about us to make an informed investment decision. We did not engage in any public solicitation or general advertising. No registration rights were granted to any of the purchasers. We issued the stock certificates and affixed the appropriate legends to the restricted stock.

Item 3. Defaults upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted for a vote to our security holders during the reporting period.

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits

Exhibit Number	Description
10.1	Letter of Intent with Dermal Defense ¹
31.	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

¹ Previously filed as an exhibit to Form 10-KSB filed on April 14, 2004.

(b) Reports on Form 8-K

We did not file any Current Reports on Form 8-K during the quarter ended March 31, 2004 and we have not filed any Current Reports on Form 8-K since March 31, 2004.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SKINVISIBLE, INC.

Date: May 17, 2004

/s/ Terry Howlett

Financial

Terry Howlett
Chief Executive Office, Chief

Officer, and Director